GlaxoSmithKline PLC (GSK): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

GlaxoSmithKline ( GSK) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole was unchanged today. By the end of trading, GlaxoSmithKline rose $0.64 (1.2%) to $54.81 on light volume. Throughout the day, 1,672,567 shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2,393,300 shares. The stock ranged in a price between $54.58-$54.90 after having opened the day at $54.61 as compared to the previous trading day's close of $54.17. Other companies within the Health Care sector that increased today were: Stereotaxis ( STXS), up 18.5%, Dehaier Medical Systems ( DHRM), up 14.7%, Ultragenyx Pharmaceutical ( RARE), up 11.6% and Skystar Bio-Pharmaceutical Company ( SKBI), up 11.3%.

GlaxoSmithKline plc manufactures and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $128.7 billion and is part of the drugs industry. Shares are up 1.5% year to date as of the close of trading on Tuesday. Currently there is 1 analyst that rates GlaxoSmithKline a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, increase in stock price during the past year, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the negative front, Ventrus Biosciences ( VTUS), down 63.0%, OxiGene ( OXGN), down 24.6%, Galena Biopharma ( GALE), down 16.4% and Stemline Therapeutics ( STML), down 12.1% , were all laggards within the health care sector with Regeneron Pharmaceuticals ( REGN) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

These Stocks Pay You to Own Them

Nascar Champ Danica Patrick--'I'm Not That Into Cars'

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

Hikma Sinks on Advair Generic Concerns

Shire Gains as it Seeks European Approval For Dry Eye Treatment